Skip to main content
OpenTrials

Clinical trial condition

Lentivirus Infections

Explore clinical trials studying Lentivirus Infections. Study availability and eligibility vary by location and protocol.

5,647 public trials 305 recruiting studies
Refine in advanced search Browse all conditions

Lentivirus Infections trial results

Completed

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study

NCT03067285

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Hospital Puerta de Hierro Majadahonda, Madrid, Spain
  • Hospital Fundación Jimenez Díaz Madrid, Spain
  • Hospital Ramón y Cajal Madrid, Spain
  • Hospital Univ. Infanta Leonor Madrid, Spain
View Trial Details
Completed

HIV&HEART Aging Study (12,5 Year Follow up)

NCT04156048

Conditions
AIDS Dementia Complex, Acquired Immunodeficiency Syndrome, Aging, +34 more
Locations
  • Universitätsklinikum Essen, Klinik für Dermatologie Essen, Nordrheinwestfalen, Germany
  • University Hospital of Bochum, Department of Dermatology Bochum, North Rhine-Westphalia, Germany
  • HIV physician pratice Duisburg, North Rhine-Westphalia, Germany
  • Institut für Medizinische Informatik, Biometrie und Epidemiologie Essen, North Rhine-Westphalia, Germany
View Trial Details
Completed

HIV Awal (Early) Testing & Treatment Indonesia Project Intervention Phase

NCT03659253

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • Yayasan Kerti Praja Denpasar, Bali, Indonesia
  • Dr. Sardjito Hospital, Yogyakarta Indonesia Yogyakarta, DI Yogyakarta, Indonesia
  • Atma Jaya HIV-AIDS Research Centre Jakarta, DKI Jakarta, Indonesia
  • Hasan Sadikin Hospital, Bandung, Indonesia Bandung, West Java, Indonesia
View Trial Details
Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Bakersfield, California, United States
View all 48 locations
View Trial Details
Completed

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • South Flordia Childrens Diagnostic & Treatment Center Fort Lauderdale, Florida, United States
  • Tulane University New Orleans, Louisiana, United States
  • St Jude's Children's Research Hospital Memphis, Tennessee, United States
  • University of Washington Medical Center Seattle, Washington, United States
View all 19 locations
View Trial Details
Completed

123I Radiolabeled 3BNC117

NCT03468582

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • Centre Hospitalier Universitaire Vaudois Lausanne, Canton of Vaud, Switzerland
View Trial Details

Related conditions